The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity

被引:33
|
作者
Blanter, Julia B. [1 ]
Frishman, William H. [2 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[2] Westchester Med Ctr, New York Med Coll, Dept Med, Valhalla, NY USA
关键词
cardiotoxicity; chemotherapy; beta-adrenergic blockers; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; VENTRICULAR SYSTOLIC DYSFUNCTION; BREAST-CANCER; HEART-FAILURE; CARDIO-ONCOLOGY; DOXORUBICIN; CARVEDILOL; THERAPY; CANDESARTAN; ENALAPRIL; TRIAL;
D O I
10.1097/CRD.0000000000000252
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anthracycline (doxorubicin) and trastuzumab treatments for cancer patients have been known to cause cardiotoxicity. The current recommendations for prevention of cardiac events from cancer chemotherapies are largely based on opinion. The American Society of Clinical Oncology recommends active screening and prevention of modifiable cardiovascular risk factors. The risk factors are defined as tobacco use, high blood pressure, high cholesterol, alcohol use, obesity, and physical inactivity. Beta-adrenergic blockers and angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) have been the mainstay of treatment for heart failure patients with reduced left ventricular ejection fraction for many years. This review analyzed the use of beta-adrenergic blockers and ACE inhibitors/ARBs as protection against cardiomyopathy caused by anthracyclines and trastuzumab. Although many more studies are warranted, it was concluded that the addition of a beta-blocker early in the treatment of cancer patients who are undergoing anthracycline or trastuzumab treatment can have beneficial effects in preserving left ventricular ejection fraction and preventing chemotherapy-induced cardiotoxicity. The effects are more apparent in the short term. More studies of the long-term effects are warranted, as are the additive effects of using a beta-blocker and ACE inhibitor/ARB together to prevent chemotherapy-induced cardiotoxicity.
引用
收藏
页码:256 / 259
页数:4
相关论文
共 50 条
  • [31] Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension?
    Kaplan, NM
    JOURNAL OF HUMAN HYPERTENSION, 2000, 14 (Suppl 1) : S87 - S90
  • [32] The Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes
    Padwal, Raj
    Lin, Mu
    Eurich, Dean T.
    JOURNAL OF CLINICAL HYPERTENSION, 2016, 18 (03) : 200 - 206
  • [33] Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
    Li, Xiao-Long
    Li, Tao
    Du, Qi-Cong
    Yang, Li
    He, Kun-Lun
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (20) : 5462 - 5469
  • [34] Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Treatment of Hypertension: Should they be Used Together?
    Verdecchia, Paolo
    Angeli, Fabio
    Mazzotta, Giovanni
    Ambrosio, Giuseppe
    Reboldi, Gianpaolo
    CURRENT VASCULAR PHARMACOLOGY, 2010, 8 (06) : 742 - 746
  • [35] Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers
    Diav-Citrin, Orna
    Shechtman, Svetlana
    Halberstadt, Yehudit
    Finkel-Pekarsky, Victoriya
    Wajnberg, Rebecka
    Arnon, Judy
    Di Gianantonio, Elena
    Clementi, Maurizio
    Ornoy, Asher
    REPRODUCTIVE TOXICOLOGY, 2011, 31 (04) : 540 - 545
  • [36] Renoprotective Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria
    Hsu, Feng-Yi
    Lin, Fang-Ju
    Ou, Huang-Tz
    Huang, Shih-Hui
    Wang, Chi-Chuan
    KIDNEY & BLOOD PRESSURE RESEARCH, 2017, 42 (02) : 358 - 368
  • [37] Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease
    Ferrari, Paolo
    NEPHROLOGY, 2007, 12 (01) : 81 - 89
  • [38] Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: A case series and literature review
    Palleria, Caterina
    Bennardo, Luigi
    Dastoli, Stefano
    Iannone, Luigi F.
    Silvestri, Martina
    Manti, Antonia
    Nistico, Steven P.
    Russo, Emilio
    De Sarro, Giovambattista
    DERMATOLOGIC THERAPY, 2019, 32 (01)
  • [39] Combination Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Diabetic Kidney Disease
    Stanton, Robert C.
    CURRENT DIABETES REPORTS, 2013, 13 (04) : 567 - 573
  • [40] Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and risk of appendicitis
    Mukamal, Kenneth J.
    Ghimire, Sanjay
    Pandey, Rudra
    Fiarman, Gale S.
    Gautam, Shiva
    ANNALS OF EPIDEMIOLOGY, 2012, 22 (10) : 747 - 750